Previous Close | 35.49 |
Open | 35.43 |
Bid | 0.00 x 1100 |
Ask | 0.00 x 1100 |
Day's Range | 34.87 - 35.61 |
52 Week Range | 28.47 - 46.97 |
Volume | |
Avg. Volume | 5,210,877 |
Market Cap | 71.997B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 13.07 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.90 (5.34%) |
Ex-Dividend Date | Nov 17, 2022 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for GSK
WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a license agreement with GSK plc (LSE/NYSE: GSK) under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms.
COVID-19 may have lost its daily news headline status, but the disease rages on with 2700 weekly deaths in the U.S. and millions of Americans chronically disabled from long-COVID, 4 million of whic...
Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties Collaboration brings together Wave’s PRISM™ oligonucleotide platform and GSK’s expertise in genetics and genomics GSK to advance up to eight preclinical programs Additionally, GSK receives exclusive global license to Wave’s preclinical, potential first-in-class RNA editing program, WVE-006, to treat alpha-1 antitrypsin deficiency, a disease that impacts the lungs and liver